2023 World Conference on Lung Cancer (Posters)-EP07.04. Telomerase-Based Circulating Tumor Cell Detection for the Treatment Response Prediction in Patients with Non-small-Cell Lung Cancer

EP07.04. Telomerase-Based Circulating Tumor Cell Detection for the Treatment Response Prediction in Patients with Non-small-Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This presentation at the WCLC 2023 conference focuses on the use of telomerase-based circulating tumor cell (CTC) detection as a predictor of treatment response in patients with non-small cell lung cancer (NSCLC). The researchers developed a highly sensitive and specific CTC detection system using TelomeScan, a telomerase-specific adenovirus. They evaluated different CTC subtypes using phenotypic markers and assessed the relationship between clinicopathological variables and prognostic values of CTCs.<br /><br />The results showed that 92.4% of advanced NSCLC patients had CTCs at baseline, with 63.0% of patients having a total CTC count of 3 cells or more per 3 mL of blood. The baseline CTC count was found to be an independent prognostic factor for progression-free survival and overall survival. PD-L1-CTCs and EMT-CTCs were detected in 75% and 12% of patients, respectively. The sensitivity/specificity of total CTCs and PD-L1-CTCs compared to control individuals were high.<br /><br />The presence of baseline CTC counts, baseline PD-L1-EMT-CTC counts, and changes in PD-L1-CTC count during front-line treatment were associated with poor prognosis and recurrence. Dynamic changes in PD-L1-CTC count after two cycles of treatment were significantly associated with partial response and progressive disease.<br /><br />The researchers concluded that TelomeScan-guided CTC measurements can be recommended as an early and sensitive predictor of poor prognosis in NSCLC patients at high risk of treatment recurrence. Detection of PD-L1-CTCs could help predict the response or resistance to front-line treatment, potentially optimizing the choice of precision medicines for advanced NSCLC patients.<br /><br />In summary, the study highlights the potential of telomerase-based CTC detection as a non-invasive liquid biopsy to predict treatment responses and guide personalized medicine choices in patients with non-small cell lung cancer.

Asset Subtitle

Kazuaki Hoshi

Meta Tag

Speaker Kazuaki Hoshi

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

telomerase-based CTC detection

treatment response predictor

non-small cell lung cancer

TelomeScan

CTC subtypes

prognostic values

PD-L1-CTCs

EMT-CTCs

recurrence

precision medicines